Skip to main content

Assays for the Screening and Characterization of Tau Aggregation Inhibitors

  • Protocol
  • First Online:
Tau Protein

Abstract

Aggregation of tau protein is a pathological hallmark of Alzheimer’s disease and other neurodegenerative tauopathies. Inhibition of tau aggregation may provide a method for treatment of these disorders. Methods to identify tau aggregation inhibitors (TAIs) in vitro are useful and here we describe assays for TAIs using purified recombinant tau protein fragments in a cell-free immunoassay format and in a stably transfected cell model to create a more physiological environment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Buée L, Bussière T, Buée-Scherrer V et al (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 33:95–130

    Article  PubMed  Google Scholar 

  2. Novak M, Kabat J, Wischik CM (1993) Molecular characterization of the minimal protease resistant tau unit of the Alzheimer’s disease paired helical filament. EMBO J 12:365–370

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Wischik CM, Novak M, Thøgersen HC et al (1988) Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer’s disease. Proc Natl Acad Sci U S A 85:4506–4510

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Mukaetova-Ladinska EB, Garcia-Sierra F, Hurt J et al (2000) Staging of cytoskeletal and β-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer’s disease. Am J Pathol 157:623–636

    Google Scholar 

  5. Arriagada PW, Growdon JH, Hedley-White ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42:631–639

    Article  CAS  PubMed  Google Scholar 

  6. Wilcock GK, Esiri MM (1982) Plaques, tangles and dementia: a quantitative study. J Neurol Sci 56:343–356

    Article  CAS  PubMed  Google Scholar 

  7. Maruyama M, Shimada H, Suhara T et al (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79:1094–1108

    Article  CAS  PubMed  Google Scholar 

  8. Okamura N, Furumoto S, Fodero-Tavoletti MT et al (2014) Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using F-18-THK5105 PET. Brain 137:1762–1771

    Article  PubMed  Google Scholar 

  9. Wischik CM, Edwards PC, Lai RYK et al (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A 93:11213–11218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Wischik CM, Schelter BO, Wischik DJ et al (2018) Modeling prion-like processing of tau protein in Alzheimer’s disease for pharmaceutical development. J Alzheimers Dis 62:1287–1303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Bulic B, Pickhardt M, Mandelkow E (2013) Progress and developments in tau aggregation inhibitors for Alzheimer disease. J Med Chem 56:4135–4155

    Article  CAS  PubMed  Google Scholar 

  12. Taniguchi S, Suzuki N, Masuda M et al (2005) Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 280:7614–7623

    Article  CAS  PubMed  Google Scholar 

  13. Harrington CR, Storey JMD, Clunas S et al (2015) Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of Alzheimer’s disease. J Biol Chem 290:10862–10875

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Melis V, Magbagbeolu M, Rickard JE et al (2015) Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav Pharmacol 26:353–368

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Brandt R, Kempf M, Lee G (1997) Expression and purification of tau for in vitro studies. In: Avila J, Brandt R, Kosik KS (eds) Brain microtubule associated proteins: modifications in disease. Harwood Academic Publishers, Amsterdam, pp 245–257

    Google Scholar 

  16. Novak M, Jakes R, Edwards PC et al (1991) Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of mAbs 423 and 7.51. Proc Natl Acad Sci U S A 88:5837–5841

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Harrington CR, Edwards PC, Wischik CM (1990) Competitive ELISA for measurement of tau proteins in Alzheimer’s disease. J Immunol Meth 134:261–271

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Charles R. Harrington .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2024 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Horsley, D., Rickard, J.E., Vorley, T., Leeper, M.F., Wischik, C.M., Harrington, C.R. (2024). Assays for the Screening and Characterization of Tau Aggregation Inhibitors. In: Smet-Nocca, C. (eds) Tau Protein. Methods in Molecular Biology, vol 2754. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3629-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-3629-9_5

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-3628-2

  • Online ISBN: 978-1-0716-3629-9

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics